arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CAPRICOR THERAPEUTICS, INC.

CAPR
$4.10 ▼ -0.08 (-2.03%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
80 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CAPRICOR THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $235.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -13.2%
FCF / Share $-0.60
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

80-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.13M
↓ -7.9%
Net Income Profit after all expenses
$-33.94M
↓ -39.2%
Operating Margin Operating profit as % of sales
-69.1%
↑ +76.3%
FCF / Share Free cash flow per share
$-0.60
↓ -272.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 21 years · 80 quarters